Abstract
BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-alpha] diazepine-1,4], a novel platelet-activating factor (PAF) receptor antagonist with a hetrazepine structure, decreased the maximal number of binding sites (Bmax) of [3H]PAF in rabbit platelet membranes without altering its dissociation constant. Platelet aggregation induced by 1 microM PAF was prevented by preincubation with 1 microM BN 50730. The washing of the platelets preincubated with BN 50730 failed to revert its inhibitory effects. We conclude that BN 50730 acts as a non-competitive antagonist of the PAF receptor, due to the formation of a highly stable drug-receptor complex.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Azepines / chemistry
-
Azepines / pharmacology*
-
Binding Sites
-
Blood Platelets / metabolism*
-
Cell Membrane / metabolism
-
Platelet Activating Factor / antagonists & inhibitors
-
Platelet Aggregation Inhibitors / chemistry
-
Platelet Aggregation Inhibitors / pharmacology*
-
Platelet Membrane Glycoproteins / antagonists & inhibitors*
-
Platelet Membrane Glycoproteins / chemistry
-
Rabbits
-
Receptors, Cell Surface*
-
Receptors, G-Protein-Coupled*
-
Thienopyridines
-
Triazoles / chemistry
-
Triazoles / pharmacology*
Substances
-
Azepines
-
Platelet Activating Factor
-
Platelet Aggregation Inhibitors
-
Platelet Membrane Glycoproteins
-
Receptors, Cell Surface
-
Receptors, G-Protein-Coupled
-
Thienopyridines
-
Triazoles
-
platelet activating factor receptor
-
BN 50730